Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (617)	1/25/2007 1:09:58 PM
From: zeta1961	Respond to of 802

You were reading my mind..I was wondering what would it take for INGN to commence combo Avastin trials..I also imagined the negotiations with Nance and DNA execs-g- Thanks..very much looking forward to it..Looking forward to sharing un cafe with these folk-g- cyclingnews.com Elisabeth

To: Jibacoa who wrote (617)	1/26/2007 2:29:08 PM
From: zeta1961	Read Replies (1) \| Respond to of 802

Bernard, I found the actual paper for the Mda7-Avastin mice studies..I'm more impressed than yesterday..caveat, I rarely get to read full length preclinicals so I don't have much to compare..Avastin was given by intraperitoneal route.. nature.com In fact, the tumors in all of the Ad-mda7 plus bevacizumabtreated mice completely regressed within the first 4 weeks (28 days) of initiation of treatment, and all of the mice remained tumor free for an additional 48 days, at which time the experiment was terminated. The tumor regression was consistent in all animals treated with the combination, whereas no complete regressions were observed in any other treatment group. Moreover, adverse effects such as body weight loss, morbidity, or death were evaluated for each agent and combination. No decrease in body weight or morbidity was observed, indicating that all treatments were tolerated. An alternate method for evaluating effects of anticancer agents is to analyze tumor growth delay (TGD), i.e., compare the time required for tumors to achieve 200mm3.20 Both PBS and Ad-luc controls gave a TGD of 8 days, whereas Ad-mda7 or bevacizumab monotherapy produced a TGD of 12 days. The combination of Ad-luc plus bevacizumab also demonstrated a TGD of 12 days whereas Ad-mda7 plus bevacizumab treatment produced a TGD of greater than 76 days. From our previous experience with this model, if animals are tumor free for more than 40 days, they do not regrow tumors and are cured. These results showed that treatment of lung tumors with Ad-mda7 plus bevacizumab produces synergistic antitumor activity in vivo, resulting in complete and prolonged tumor regression.